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Key messages
What is already known on this subject?
 ► Good quality clinical practice guidelines on diagno-
sis, monitoring and treatment of Ehlers-Danlos syn-
dromes really need to optimise patient care.
What does this study add?
 ► The systematic literature revision detected the ab-
sence of papers reporting good quality clinical prac-
tice guidelines to optimise Ehlers-Danlos syndrome 
patient care.
How might this impact on clinical practice?
 ► A large area of unmet needs for both clinicians and 
patients have been identified, including correct di-
agnosis and classification, clinical management, 
medical/pharmacological management, rehabilita-
tion care in expert centres and coordination of the 
multidisciplinary approach.
ABSTRACT
Objective To report the effort of the European Reference 
Network for Rare and Complex CONnective tissue and 
musculoskeletal diseases NETwork working group on 
Ehlers-Danlos syndromes (EDS) and related disorders to 
assess current available clinical practice guidelines (CPGs) 
specifically addressed to EDS, in order to identify potential 
clinician and patient unmet needs.
Methods Systematic literature search in PUBMED and 
EMBASE based on controlled terms (MeSH and Emtree) 
and keywords of the disease and publication type (CPGs). 
All the published articles were revised in order to identify 
existing CPGs on diagnosis, monitoring and treatment of 
EDS.
Results Literature revision detected the absence of 
papers reporting good quality CPGs to optimise EDS patient 
care. The current evidence-based literature regarding 
clinical guidelines for the EDS was limited in size and 
quality, and there is insufficient research exploring the 
clinical features and interventions, and clinical decision-
making are currently based on theoretical and limited 
research evidences.
Conclusions Many clinician and patient unmet needs 
have been identified.
INTRODUCTION
Rare and Complex CONnective tissue 
and musculoskeletal diseases NETwork 
(ReCONNET) is the European Reference 
Network (ERN) funded by the European 
Union’s Health Program to better promote 
healthcare, define proper organisational 
assessment and identify standard and 
cost-eﬀective pathways for the management of 
rare and complex connective tissue diseases.
Rare and complex connective tissue 
diseases comprise a large number of diseases 
and syndromes including hereditary (Ehlers-
Danlos syndromes and related disorders), 
rare systemic immune-mediated diseases 
(recurrent polychondritis, systemic sclerosis, 
mixed connective tissue disease, inflamma-
tory idiopathic myopathies, undifferentiated 
connective tissue diseases, antiphospholipid 
syndrome) and systemic autoimmune 
diseases characterised by a complex clin-
ical picture (systemic lupus erythematosus, 
Sjögren syndrome).
The Ehlers-Danlos syndromes (EDS) and 
related disorders include a clinically vari-
able and genetically heterogeneous group of 
rare hereditary monogenic connective tissue 
disorders characterised by remarkable joint 
hypermobility, abnormal skin texture and 
tissue fragility (including skin fragility with 
abnormal scarring, vascular fragility with easy 
bruisability and a variable bleeding tendency) 
and other manifestations of generalised soft 
connective tissue fragility.1 Depending on 
the EDS subtype and the underlying genetic 
defect, these manifestations and their conse-
quences may vary from almost subclinical to 
severely debilitating and even life-threatening 
diseases.
In 1997, six EDS subtypes were defined, 
including the classical, vascular, hypermo-
bility, kyphoscoliosis, arthrochalasia and 
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dermatosparaxis subtype, and clinical diagnostic criteria 
were established for each of these subtypes (the ‘Ville-
franche Classification for EDS’). Most of these condi-
tions were shown to be caused by biochemical and/or 
molecular defects in fibrillar collagen types I, III and 
V, or in their modifying enzymes.2 The advent of next 
generation sequencing into genetic research and diag-
nostics expanded the knowledge on the molecular basis 
of EDS and increased the number of patients with a 
laboratory-proven diagnosis. In March 2017, an updated 
International Classification of EDS and related disorders 
identified 13 variants with mutations in 19 distinct genes.3 
It has become clear that various molecular pathways are 
involved in the aetiology of these disorders, as many EDS 
variants are caused by mutations in genes involved in 
collagen biogenesis and in that of other molecules of the 
extracellular matrix, such as tenascin-X.1 4
Many patients with EDS, however, still remain without 
a laboratory confirmation. This is especially true for 
the patients with hypermobile EDS, probably the most 
common EDS subtype. This lack of knowledge contrib-
utes to the patients’ burden. Furthermore, many indi-
viduals with symptomatic joint hypermobility and/or 
features of EDS do not meet the criteria incorporated 
in the new EDS nosology and remain without an “iden-
tity”. However, among them subjects presenting with 
specific secondary musculoskeletal manifestations are 
now labelled with the descriptive term of “hypermobility 
spectrum disorders”. At present, hypermobility spectrum 
disorders are variable conditions “at bridge” between 
non-syndromic, asymptomatic joint hypermobility and 
the hypermobile EDS.5 Also clinical management is 
supported by low-evidence data.
Clinical practice guidelines (CPGs) are systematically 
developed statements that include recommendations 
to assist practitioner and patient decisions about appro-
priate healthcare for specific clinical circumstances.6 
They are informed by a systematic review of evidence and 
an assessment of the benefits and harms of alternative 
care options.7
Good quality CPGs on diagnosis, monitoring and treat-
ment of EDS really need to optimise patient care.
The aim of this paper was to report the effort of the 
ERN ReCONNET working group on EDS to identify 
current available good CPGs specifically addressed to 
EDS, in order to identify potential clinician and patient 
unmet needs.
METHODS
Systematic literature search
The literature revision and analysis to search for CPGs was 
performed during the last 6 months of 2017, coordinated 
by a regular interaction between participants of the EDS 
working group, including the healthcare provider (HCP) 
and the ERN ReCONNET team. The work was regularly 
assessed and discussed during meetings (European 
League Against Rheumatism congress 2017, American 
College of Rheumatology congress 2017, ReCONNET 
meeting in Pisa on February 2018), web conferences, 
electronic letters and the ERN Collaborative Platform.
We carried out a systematic search in PUBMED and 
EMBASE based on controlled terms (MeSH and Emtree) 
and keywords of the disease and publication type (CPGs). 
We reviewed all the published articles (English language) 
in order to identify existing CPGs on diagnosis, moni-
toring and treatment, according to the Institute of Medi-
cine 2011 definition (CPGs are statements that include 
recommendations intended to optimise patient care that 
are informed by a systematic review of evidence and an 
assessment of the benefits and harms of alternative care 
options).
The Disease Coordinator (DC) of the ERN-Re-
CONNET for EDS had assigned the work on CPGs to 
the HCPs involved. Moreover, in order to implement the 
list of guidelines provided by MEDLINE and EMBASE 
search, the group performed also a hand search. A first 
screening among papers included in the final list (system-
atic search+hand search) based on title and abstract 
selected evidence-based medicine guidelines. A general 
assessment of the CPGs has been performed following 
the Appraisal of Guidelines for Research & Evaluation II 
(AGREE II) tool checklist not for formal appraisal but 
only to inform discussion. A discussion group was set for 
the evaluation of the existing CPGs and to identify the 
unmet needs.
Here below the search strategy
MEDLINE (PUBMED): (Ehlers([All Fields] AND 
Danlos[All Fields)]) AND (“Practice Guideline”[Publi-
cation Type] OR “Practice Guidelines As Topic”[MeSH 
Terms] OR Practice Guideline[Publication Type] OR 
“Practice Guideline”[Text Word] OR “Practice Guide-
lines”[Text Word] OR “Guideline”[Publication Type] 
OR “Guidelines As Topic”[MeSH Terms] OR Guide-
line[Publication Type] OR “Guideline”[Text Word] 
OR “Guidelines”[Text Word] OR “Consensus Develop-
ment Conference”[Publication Type] OR “Consensus 
Development Conferences As Topic”[MeSH Terms] OR 
“Consensus”[MeSH Terms] OR “Consensus”[Text Word] 
OR “Recommendation”[Text Word] OR “Recommenda-
tions”[Text Word] OR “Best Practice”[Text Word] OR 
“Best Practices”[Text Word]). EMBASE : (‘ehlers danlos’) 
AND (‘practice guideline’/exp OR ‘practice guideline’ 
OR ‘practice guidelines’/exp OR ‘practice guidelines’ 
OR ‘clinical practice guideline’/exp OR ‘clinical practice 
guideline’ OR ‘clinical practice guidelines’/exp OR ‘clin-
ical practice guidelines’ OR ‘clinical practice guidelines 
as topic’/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline’/exp OR ‘guideline’ OR ‘guidelines’/exp 
OR ‘guidelines’ OR ‘guidelines as topic’/exp OR ‘guide-
lines as topic’ OR ‘consensus development’/exp OR 
‘consensus development’ OR ‘consensus development 
conference’/exp OR ‘consensus development confer-
ence’ OR ‘consensus development conferences’/exp OR 
‘consensus development conferences’ OR ‘consensus 
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Figure 1 Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed 
to Ehlers-Danlos Syndromes (EDS) on diagnosis, monitoring and treatment, according to the Institute of Medicine 2011 
definition (ref. 7).
development conferences as topic’/exp OR ‘consensus 
development conferences as topic’ OR ‘consensus’/exp 
OR ‘consensus’ OR ‘recommendation’ OR ‘recommen-
dations’) AND [EMBASE ]/lim NOT [MEDLINE ]/lim.
The first step of the activity was the identification of 
existing clinical guidelines properly addressed to EDS.
The literature revision by searching key words in 
PUBMED , Medline and EMBASE (eg, Ehlers-Danlos, 
guidelines, recommendations, clinical practice, best prac-
tice, consensus, assessment, diagnosis, monitoring, treat-
ment) identified 193 articles by title and abstract. Among 
these, 70 papers were selected for an accurate evaluation 
of their content, and only 24 articles published between 
2012 and 2017 were finally chosen,3 5 8–29 and pdf files 
acquired, for their review in order to identify existing 
CPGs on diagnosis, monitoring and treatment, according 
to the Institute of Medicine 2011 definition (figure 1).7
RESULTS: STATE OF THE ART ON CPGS
Identification of existing CPGs
The internal evaluation of the 24 articles by the ERN 
ReCONNET EDS network participants detected the 
absence of papers reporting good quality CPGs to opti-
mise EDS patient care.
Practically, the current evidence-based literature 
regarding clinical guidelines for the EDS was limited 
in size and quality, and there is insufficient research 
exploring the clinical features and interventions, and 
clinical decision-making are currently based on theoret-
ical and limited research evidences.
UNMET NEEDS
Clinicians' unmet needs
This is the first review providing an overview of currently 
available CPGs for EDS. The term EDS includes a 
clinically variable and genetically heterogeneous group 
of hereditary connective tissue disorders, represented 
by at least 13 different EDS subtypes. The disorders are 
rare, literature scarce and good quality CPGs lacking.30 
According to this lack of information, a large number 
of unmet needs for both clinicians and patients may be 
identified, as follows.
There is a lack of good data on prevalence, natural 
history, clinical features, cardiac and vascular complica-
tion risk, medical treatments, surgery and pregnancy in 
EDS.
Web-based registries of EDS are lacking, and the real 
prevalence and clinical features of the disorders are diffi-
cult to estimate.
Elucidation of the pathogenesis of features impacting 
the quality of life of the affected individuals might 
increase medical care.
Identification of clinically reliable biomarkers could help 
physicians to early and properly diagnose and prognosti-
cate the disorders. Furthermore, advanced instrumental 
imaging techniques should be implemented in EDS care.
There is a need for medical community education and 
advise, also to instruct practitioners to correctly individ-
uate potential patients with EDS or at least once suspected 
the diagnosis to direct the patient to the referral centres.
Furthermore, at present, there is no consensus on the 
best practice for medical surveillance, medical intervention 
or for surgical intervention concerning the different EDS 
subtypes.
Future research should focus on the elucidation of the 
pathogenesis of features impacting quality of life of the 
affected individuals, diagnosis and progression at different 
ages, and on the identification of clinically reliable 
biomarkers and targetable signalling pathways and cellular 
processes for possible personalised therapies. Particular 
attention should be put on pain, fatigue and cardiovascular 
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Box 1 Possible managing of the unmet needs in Ehlers-
Danlos Syndromes (EDS)
 ► To create web-based registries to understand the real prevalence 
of the EDS.
 ► To elucidate risk factors and pathogenesis of clinical features im-
pacting the quality of life.
 ► To identify clinically reliable biomarkers of the EDS. To implement 
advanced instrumental imaging techniques for EDS diagnosis.
 ► To identify targetable signalling pathways and cellular processes to 
be applied to precision medicine.
 ► To develop professional educational programmes for general prac-
titioners, to correctly individuate potential patients with EDS and 
direct them to referral centers.
 ► To develop evidence-based recommendations for the assessment 
and management of EDS.
 ► To develop networks to let patients have a fast access to cor-
rect diagnosis and treatment, as well as a multidisciplinary care 
management.
complications of EDS. In addition, the development of 
evidence-based recommendations for the assessment and 
management of these disorders is critical for optimising 
clinician activities and improving patient health status.
Patients' unmet needs
The EDS nosology was redefined in 2017 into 13 rare and 
complex hereditary connective tissue disorders with a prev-
alence ranging from about 1:5000 to ultra-rare where only 
few patients or families in the world have been identified. A 
14 type was added in 2018.
Although the new nosology has brought attention to 
EDS, patients still have trouble to find fast access to correct 
diagnosis and treatment. Not many physicians have been 
trained to recognise EDS or do not know how to treat it. In 
many European countries and beyond, there are no diag-
nostic centres or experts available to patients.
Some of the rarer types can have life-threatening compli-
cations and are often only recognised when a (near) deadly 
event has occurred (eg, in the vascular type of EDS). As 
there is little or almost no educational information avail-
able for healthcare professional and patients, there are 
many unmet needs in this matter.
Most patients with EDS suffer from generalised joint 
hypermobility, chronic widespread pain and fatigue. Pain 
treatment is complex and usually requires guidance of a 
specialised pain clinic and the support of an integrate 
rehabilitation programme. Clinical experience suggests 
that medical marijuana may be a successful alternative to 
opioids. However, in many countries in the EU, this treat-
ment is not available.
Because of the tissue fragility, conservative treatment is 
preferred over surgery. To improve daily life functioning, 
many patients need orthotics to stabilise hypermobile 
joints, mobility aids, aids for self care and household, etc. 
Unfortunately, the needs of patients are often misunder-
stood, because their main problems are ‘invisible’. For 
instance, joint hypermobility is difficult to observe, unless 
evaluated with specific clinical tests.
At present, EDS is not curable, but only ‘treatable’. 
Patients presenting pain require multidisciplinary care, 
including pain medication, intensive physiotherapy, podi-
atry, psychology, occupational therapy and adequate 
bracing. Often a holistic or alternative approach (eg, oste-
opathy) is complimentary to normal treatment. Unfortu-
nately, many treatment options are not reimbursed, even 
when they improve the quality of life of patients with EDS 
significantly.
At present, a good number of patients are not taken 
seriously or even accused of hypochondria, Munchausen 
or Munchausen-by-proxy. As such, psychiatric diagnoses 
sometimes precede the actual diagnosis. Furthermore, 
psychological follow-up is sometimes needed, considering 
the fact that the long road to the correct diagnosis, and 
correct treatment of the symptoms often contributes to 
anxiety and depression.
In conclusion, there is a long road ahead for the EDS 
Community. Many needs are unfulfilled, including access 
to care and treatment, educational therapy, professional 
educational programme and awareness. With a strong ERN 
along with patients, experts, healthcare centres and patient 
organisations as partners, these goals can be accomplished 
over time.
CONCLUSIONS
This review shows the current lack of good quality 
CPGs on EDS and a large area of unmet needs for both 
clinicians and patients. The main critical areas include 
correct diagnosis and classification, clinical manage-
ment, medical/pharmacological management, rehabil-
itation care in expert centres and coordination of the 
multidisciplinary approach.
Possible ways to manage the unmet needs in EDS are 
reported in box 1.
In September 2018, The International Symposium on 
the EDS in Ghent Belgium reviewed the state-of-the-art 
and the new research on clinical advances and the molec-
ular and pathogenic mechanisms underlying EDS, and 
related syndromes were discussed attempting to reach at 
least some areas of the unmet needs.
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